(Nasdaq: NRWS), (OTCBB: PWRM), (OTCBB: HMBT).

RealPennies.com: Turning Pennies into dollars: (Nasdaq: NRWS), (OTCBB: PWRM), (OTCBB: HMBT).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://nrws.realpennies.com

Narrowstep Inc. (Nasdaq: NRWS)(January 16, 2008), the TV on the Internet company, announced earlier today that it has entered into a partnership with Fox International's BabyTV, to provide their original programming over the Internet using Narrowstep's platform.

BabyTV, www.babytvchannel.com, is the world's first TV channel dedicated to infants and toddlers. Their innovative programming is created by a team of award-winning content and child development experts designed to promote learning, activity, interaction and fun.

BabyTV which launched internationally in 2005, is already viewed by parents and babies worldwide on over 100 platforms in 65 different countries and in 12 different languages. The channel is also available through VOD, mobile, broadband, home videos, inflight services, and now on www.babytvchannel.com.

Narrowstep will provide BabyTV with their telvOS Internet TV platform, which is the most complete end-to-end solution for broadcasters to deliver video over the Internet. telvOS provides broadcasters with a suite of products and tools which includes a robust content management system, superior DRM tools and a host of monetization tools. These tools allow broadcasters to effectively integrate a customized Internet TV strategy into their existing workflow without the need to deal with multiple vendors.

Narrowstep also designed and built the feature-rich video player. The BabyTV player is a complementary experience to viewing the channel which allows parents to choose their child's favorite programs by themes or by character, and allows parents and babies to engage in activities such as Baby Karaoke, sing along and more. The player also offers parents the option of tailoring their child's experience by viewing the programming in a number of different languages.

Narrowstep recently announced the release of its Player 2.7 technology designed to provide global broadcasters and telcos with the tools they need to monetize video over the internet. Fox's BabyTV is the latest addition to Narrowstep's world-class list of clients including ITV Local, Virgin, Telefonica, Sci Fi Channel, KPN, the Outdoor Channel, the Travel Channel and more.

Narrowstep Inc. (OTCBB:NRWS), the TV on the Internet company, is a leading provider of Internet TV services supporting over 180 channels worldwide. Narrowstep's proprietary technology platform delivers the highest quality, TV-like experience available on the Internet. A pioneer in delivering Internet TV, Narrowstep offers the expertise and technology to move, manage and monetize video content across the Internet. For more information about Narrowstep, please visit http://www.narrowstep.com or call 609-945-1760.

About Baby TV BabyTV is the world's first 24 hour, commercial-free channel for infants and toddlers and their parents. Created by a team of award-winning content experts and leading childhood experts, BabyTV is a unique offering of dedicated programs designed to promote early learning, activity, interaction and fun. Since its first launch, BabyTV has seen rapid growth and is currently aired on over 100 platforms in more than 65 countries worldwide. For more information please visit our website www.babytvchannel.com.

For more info: http://pwrm.realpennies.com

Earlier today Power3 Medical Products, Inc. (OTCBB: PWRM)(January 16, 2008), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, announced that they were featured on Fox26 News in Houston.

The segment focused on Power3's blood serum tests for the early detection of breast cancer and neurodegenerative diseases. News anchor Melissa Wilson toured Power3's facilities in the Woodlands, Texas and interviewed Steve Rash, CEO of Power3 along with two of the company's lead investigators, Dr. Essam Sheta and Dr. Ira Goldknopf.

During the interview, Steve Rash discussed the BC-SeraPro early detection test for breast cancer. "It is a goal of Power3 Medical to help women because breast cancer is such a terrible disease and there is so much emphasis on the disease," said Rash. "This test can detect it earlier, which should result in better patient outcomes for breast cancer in most women."

The piece discussed the need for alternative methods of early detection, citing that some research has found that current methods detect breast cancer after abnormal cells have been in the body for six to ten years. In addition to BC-SeraPro, the piece highlights the company's NuroPro series of blood serum tests for the early detection of neurodegenerative diseases. The story also drew attention to the accuracy of the tests: BC-Sera Pro test for the early detection of breast cancer is 90% accurate; NuroPro test for neurodegenerative diseases is 90% accurate in detecting Alzheimer's disease and 100% accurate in detecting Parkinson's disease.

Dr. Goldknopf added, "If you can diagnose Neurodegenerative diseases in their earliest stages, before irreversible damage has been done, you stand a better chance of delaying the progression of the disease."

Power3 Medical Products, Inc. (OTCBB: PWRM, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro, in twelve Middle Eastern countries before the end of 2007. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas. The Company is preparing to commercialize its IP portfolio, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer's, and Parkinson's Diseases.

For more info: http://hmbt.realpennies.com

Earlier today HemoBioTech (OTCBB: HMBT)(January 16, 2008), a developmental biopharmaceutical company focused on developing and commercializing the first viable human blood substitute, announced that they have been highlighted in the January 5-11th issue of New Scientist.

The article, "Fresh Hope For Emergency Blood Substitutes" concerns HemoBioTech's lead product, HemoTech, and describes the technology platform's potential ability to become a safe, inexpensive, oxygen-carrying human blood substitute. In the piece, Chief Executive Officer Dr. Arthur Bollon indicated that in an initial foreign clinical study where patients received HemoTech comprising 25% of their blood volume, the substitute made blood vessels dilate, showed no kidney toxicity, caused no inflammation and even stimulated production of new red blood cells. HemoTech, which induces red blood cell production, is designed to provide a blood replacement when otherwise unavailable and has been showing positive results.

"We are pleased to have national publications like New Scientist find both relevance and excitement in our emerging technology," said Dr. Bollon. "Our ability to isolate and nullify the source of toxicity that has plagued many companies' past attempts creates both a significant commercial and medical opportunity that, if approved, will be a great asset to the broad blood use market."

New Scientist is a magazine publication that has been at the forefront of science and technology reporting since 1956. With New Scientist magazine, every week a comprehensive round-up of the latest science and technology news, reports, developments and research is distributed. Employing correspondents in every corner of the globe who contact leading scientists, New Scientist has the ability to scan thousands of journals and scientific websites to deliver the most up to date news to the public. Every issue provides the latest news across every field of science, features containing in-depth analysis and investigations of key scientific issues from our expert team of writers, the latest trends in emerging technologies and devices that could change the way we live and work, commentary, interviews, and job vacancies.

About HemoBioTech, Inc.

HemoBioTech is working on the development and commercialization of HemoTech, a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. HemoTech is composed of bovine hemoglobin that is chemically modified with adenosine triphosphate, adenosine, and glutathione. In addition to carrying oxygen through the bloodstream, HemoTech also induces erythropoiesis (red blood cell production). Based on preclinical studies and an initial foreign human clinical study, the company believes that HemoTech, due to its novel chemical composition, may significantly diminish or even eliminate the intrinsic toxicities that have plagued other attempts at developing blood substitutes. HemoTech is currently undergoing additional studies to confirm and possibly expand on these results. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, surgery, and other conditions. Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information visit our website at http://www.hemobiotech.com.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

RealPennies .
Telephone: 1-800-940-6559
Matt /at/ realpennies.com